Tanja Pejović

The University of Queensland — Australia

Medicine · Health Sciences

50h-index9.4kcitations386works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(199), Cancer-related molecular mechanisms research(54), Endometrial and Cervical Cancer Treatments(44), Genetic Associations and Epidemiology(26), Cancer Immunotherapy and Biomarkers(25)

Publications337 total

Supplementary Table 5 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
2025Open Access
Supplementary Table 2 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
2025Open Access
Supplementary Table 1 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
2025Open Access
Supplementary Methods 1 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
2025Open Access
Supplementary Figure 1 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
2025Open Access
Supplementary Table 6 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
2025Open Access
Supplementary Figure 2 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
2025Open Access
Supplementary Figure 3 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
2025Open Access
Supplementary Table 3 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
2025Open Access
Supplementary Figure 4 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
2025Open Access
Supplementary Table 4 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
2025Open Access
Table S1 from Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial
2025Open Access
Plasmonic Mesoporous Gold‐Based SERS Biosensor for Ovarian Cancer‐Derived Extracellular Vesicles
Small·2025· 2 citedOpen Access
Abstract 4292: Targeting YB-1 as a treatment strategy for high-grade serous ovarian carcinoma
Cancer Research·2025
A MOF-derived iron oxide nanorod platform for multiplexed detection of ovarian cancer extracellular vesicle biomarkers
Journal of Materials Chemistry B·2025· 1 cited
Minimally Invasive Surgery for the Management of Ovarian Cancer
O&G Open·2024· 3 citedOpen Access
Data from Maveropepimut-S, a DPX-based immune-educating therapy, shows promising and durable clinical benefit in patients with recurrent ovarian cancer, a phase 2 trial
2024Open Access
Table S1 from Maveropepimut-S, a DPX-based immune-educating therapy, shows promising and durable clinical benefit in patients with recurrent ovarian cancer, a phase 2 trial
2024Open Access
Table S1 from Maveropepimut-S, a DPX-based immune-educating therapy, shows promising and durable clinical benefit in patients with recurrent ovarian cancer, a phase 2 trial
2024Open Access
Reduced anti-Müllerian hormone action in cumulus-oocyte complexes is beneficial for oocyte maturation without affecting oocyte competence
Frontiers in Endocrinology·2024· 1 citedOpen Access
page 1 of 17Next →

Frequent Co-authors

Beth Y. Karlan(11), Susanne K. Kjær(9), Claus Høgdall(9), Farr Nezhat(8), Peter A. Fasching(8), Florian Heitz(8), Estrid Høgdall(8), Ellen L. Goode(8), Anna DeFazio(8), Marc T. Goodman(8), Diether Lambrechts(7), Allan Jensen(7), Felix Mitelman(7), Nils Mandahl(7), Helena Willén(7), Paulette Mhawech‐Fauceglia(7), Daniel W. Cramer(7), Susan J. Ramus(6), Yukie T. Bean(6), Jacek Gronwald(6)